Primary cardiac sarcoma is a rare malignant myocardial neoplasm that does not exhibit gender predominance or age predilection.
Introduction
Cardiac tumors can be classi ed as either primary or secondary [1] . Secondary tumors are usually metastasis from other primary sites distal to the heart and are far more prevalent than primary tumors [1] [2] [3] . Primary cardiac tumors are classi ed into benign and malignant tumors, with benign cardiac tumors comprising approximately 75% of all primary cardiac tumors [2] [3] [4] . Although rare, the bulk of malignant cardiac tumors are sarcomas, most commonly angiosarcoma and rhabdomyosarcoma, but other forms of sarcoma may also be present at times [2] [3] [4] . ese tumors do not exhibit gender predominance or age predilection, tend to grow in any location of the heart, and grow exponentially [3, 5, 6] . Distant metastasis may occur to sites such as liver, bone, and brain [6] .
Cardiac synovial sarcoma (SS) is a unique form of sarcoma that is infrequently encountered. It makes up approximately 5% of cardiac sarcomas and less than 1% of all primary cardiac tumors [7] . It is usually found in the atria, right side of the heart, or pericardial surface; arises from mesenchymal stem cells; and comprises four subcategories [1, 5] . SS remains asymptomatic until it in ltrates vital structures, obstructs cardiac output, or embolizes [3] . When symptomatic, patients can experience dyspnea, orthopnea, pyrexia, dysrhythmia, and angina [5] .
Case Presentation
A 41-year-old G2P1001 parous female whose past medical history is pertinent for remote migraines presented to our facility from an outside hospital (OSH) with complaints of sudden onset of left-sided hemiplegia, facial paralysis, and dysarthria. Her symptoms resolved spontaneously en route to the ED. e pregnancy had been uneventful except for a period approximately 6 weeks prior to presentation where she gained eight pounds in one week, prompting evaluation for preeclampsia. During that workup, she was found to have mildly elevated liver function tests (LFTs) and thrombocytopenia without hypertension or proteinuria. Serial ancillary evaluations revealed improved parameters; thus, no further inquests were made. Upon presentation to the OSH, an emergent CT head did not reveal any signs of acute disease. Labs revealed white blood cell count 8.3K/μl, hemoglobin 11. Stat pelvic ultrasound was performed upon arrival to our facility which showed normal fetal heart and respirations. MRV/MRA demonstrated a 7 × 12 mm area of acute infarct in the right posterior insular cortex with normal cerebral arteries and venous sinuses. Transthoracic echocardiography (TTE) revealed preserved ejection fraction of 65-70% and a 17 × 18 mm obstructing mobile mass possibly attached to the aortic valve or the left ventricular out ow tract (LVOT) with an aortic valve area of 0.52 cm 2 and peak and mean gradients of 57 mmHg and 33 mmHg, respectively. Followup TEE con rmed TTE ndings (Figures 1 and 2) . As a result, a shared decision was made to proceed with stat C-section at 35 w 2 d. e operation was successful yielding a healthy female infant. e next day, the patient returned to the OR for resection of the cardiac mass. Frozen section during the operation con rmed primary cardiac synovial sarcoma with histologic analysis of the cardiac mass revealing a biphasic synovial sarcoma (Figure 3 ) positive for cytokeratin and CD99 (Figures 4 and 5 ). e specimen also stained positive for calretinin and EMA. Cytogenetic testing demonstrated t(X;18)(p11.2;q11.2) gene translocation. e neoplasm involved the right coronary aortic valve lea et and both muscular and membranous parts of the IV septum (Figures 6-8) . As a result, the surgeon proceeded with the Bentall and modi ed Konno procedures after wide resection of the mass. e operation was a success, but unfortunately, the patient went into cardiorespiratory arrest on postoperative day one. She was resuscitated and placed on vasopressors and inotropes but remained pacer dependent. Unfortunately, despite aggressive treatment, the patient expired.
Discussion
e di erential diagnosis for intracardiac masses includes tumors, thrombi, vegetation, and calci c lesions amongst others [1] . Based on the size, motion, and echogenicity of the mass, it was believed to be a tumor. As previously mentioned, cardiac masses can either be of primary cardiac origin or be secondary as a result of distant metastasis. e primary tumors comprise benign and malignant tumors of which sarcoma makes up the bulk of the malignant tumors. A study determined the prevalence of primary cardiac sarcoma at autopsy to be 0.00017%, with an incidence from 0.001 to 0.03% and a general incidence from 0.07% [5] .
Based on histology, there are multiple types of cardiac sarcoma. One of the rare forms of cardiac sarcoma is Case Reports in Medicine synovial sarcoma. It has not been described extensively in literature due to its low incidence and prevalence. As the name implies, SS is of mesenchymal origin. It makes up approximately 5% of cardiac sarcomas and less than 0.1% of all primary cardiac tumors [7] . It comprises four subcategories and is commonly found in the atria, right side of the heart, or pericardial surface with left-sided occurrence a rarity [1, 5, 8, 9] . e subcategories of SS include biphasic, monophasic brous, monophasic epithelial, and poorly di erentiated [10] . All four subtypes are characterized by the composition of the two cellular elements and the degree of di erentiation. e two main cellular elements that can be seen on histology include epithelial cells and spindle cells [10, 11] . Immunohistochemical staining for epithelial and mesenchymal markers such as EMA, S-100, CD99, cytokeratin, and BCL2 (Table 1) can be used as an adjunct to histologic analysis to diagnose SS. e hallmark for diagnosing synovial sarcoma is the cytogenetic detection via FISH of the translocated chromosome t(X;18)(p11.2;q11.2) which is present on approximately 90% of synovial sarcomas [9] [10] [11] [12] . is translocation results in the fusion of the SYT gene on chromosome 18q11 with the SSX1, SSX2, or SSX4 gene on chromosome Xp11 [10, 11, 13] . Normally, the SSX and SYTgenes encode for proteins that function as transcription regulators in the cell nucleus.
e SSX codes for a transcription inhibitor protein, while the SYT codes for a transcription activator protein. e translocation results in replacement of the inhibitor region of SSX with the activator portion of SYT. It is thought that the protein from the fusion SYT-SSX oncogene likely regulates chromatin remodeling which may lead to enhanced proliferation of mesenchymal cells [11] . e fusion oncogene has also been associated with aberrant E-cadherin repression, Bcl-2 overexpression, and downregulation of Mcl1 [13] .
For all cardiac sarcomas, the de nitive therapy is excision, which may prove di cult due to the intrinsic in ltrative nature of the tumors with concomitant administration of neoadjuvant chemotherapy and radiotherapy [3, 5, 13] . In our patient, the mass was attached to the muscular septum, Case Reports in Medicinemembranous septum, and the right coronary lea et. is prompted a shared discussion between the patient, her family, and the medical team culminating in the agreement to proceed with a wide resection of the mass by removing the muscular septum, the membranous septum, and dissecting into the right ventricular out ow tract (RVOT) as a modi ed Konno procedure. After successful resection, a modi ed Bentall procedure was used to replace the aortic root along with the aortic valve via a porcine bioprosthesis, reimplant the coronary vessels, reconstruct the interventricular septum, the RVOT, and repair the tricuspid valve.
e data on neoadjuvant chemotherapy are limited due to the rarity of the disease and absence of double-blinded controlled studies. e general consensus regarding chemotherapy is administration of a combination of an anthracycline such as daunorubicin or doxorubicin and a nitrogen mustard such as cyclophosphamide or ifosfamide with the adriamycin-ifosfamide combination showing the most consistent e cacy. Despite excision and cytotoxic therapy, the likelihood of recurrence is high with several manuscripts reporting recurrence after therapy [8, 9] . Molecular targeting seems to be a great avenue for further research with the prevalence of t(X;18) translocation in SS. Several studies have shown that knockdown of the SYT-SSX oncogene results in decreased cell viability secondary to an increase in apoptosis [13] . Without treatment, prognosis is usually grim with predicted 6-24 month survival even in the presence of adjuvant therapy [5, 6, 10] .
e main prognostic factor is complete resection of the tumor [3, 5, 10] . ere have been reports of improved recurrence rate and overall survival rate with adjuvant chemotherapy [5, 10] .
Conclusion
Synovial sarcoma is a rare form of cardiac sarcoma that portends a dismal prognosis. Further studies are required to determine appropriate treatment strategies.
